Saturday, September 24, 2022
Tags Drugs and Pharmaceuticals

Tag: Drugs and Pharmaceuticals

Kalyagen Announces Attendance and Speaking Engagement at 8th Annual Biohacking Conference

AUSTIN, Texas, Sept. 13, 2022 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce that it will be attending and its founder, Christian Drapeau, will be speaking at the upcoming 8th Annual Biohacking Conference. The conference, which is completely sold out, will be held September 15-17 at The Beverly Hilton in Beverly Hills, California.

Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines

PFLUGERVILLE, Texas, May 4, 2022 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn., April 6, 2022 (SEND2PRESS NEWSWIRE) -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine.

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla., AUSTIN, Texas and MELBOURNE, Australia, April 6, 2022 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

Geminid Systems Unveils Pharmalite CRM to Boost Remote Engagement of Pharma Field Teams

REDWOOD CITY, Calif., Dec. 9, 2021 (SEND2PRESS NEWSWIRE) -- Geminid Systems, Inc. today announced the global rollout of a SaaS super-app that aims to improve pharmaceutical operations by helping field teams easily overcome challenges arising from the ongoing COVID pandemic.

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y., Sept. 10, 2021 (SEND2PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus.

Kalyagen Announces Release of Free eBook on How to Optimize Health Using Stem Cells

AUSTIN, Texas, July 14, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen® has announced the release and availability of a free eBook, "The Stemregen Effect - Tapping into the Power of Your Own Stem Cells," which provides an overview of how stem cells are the body's repair system and how STEMREGEN®, a natural stem cell enhancer, has been documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM).
C. diff. Symposium 2021

Live, Virtual C. diff. Symposium 2021 supports and guides patients, families, and caregivers through a C. difficile illness

TAMPA, Fla. /Florida Newswire/ -- The C Diff Foundation will host a free, live-online, and interactive symposium on Friday, July 16, 2021 from 1 to 3 p.m. EDT. Sponsored by Seres Therapeutics, the event is designed for patients who are being treated for a C. diff. infection (CDI) in addition to those who are recovering or who have experienced CDI recurrences.

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

AUSTIN, Texas, March 16, 2021 (SEND2PRESS NEWSWIRE) -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource ("PHIDR"), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

AUSTIN, Texas and BIRMINGHAM, Ala., March 11, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research.

Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals

AUSTIN, Texas, March 10, 2021 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Caisson Biotech, LLC and Heparinex, LLC Announce Positive Examination Report of European Patent and the Discovery of a New Class of...

AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) -- Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.

Rescindo Therapeutics’ RSC-57 Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Kabuki Syndrome

CARY, N.C., Feb. 12, 2021 (SEND2PRESS NEWSWIRE) -- Rescindo Therapeutics Inc., a drug discovery company dedicated to the development of new treatments for rare genetic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation for the Company's lead drug RSC-57, for the treatment of patients with Kabuki Syndrome.

Kalyagen Announces Launch of ‘Stem the Tide of Time’ Campaign Featuring NBA Hall of Fame Finalist Marques Johnson

AUSTIN, Texas, Feb. 8, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen is pleased to announce the launch of its "Stem the Tide of Time" social media campaign featuring former UCLA Bruin and Milwaukee Buck All-Star Marques Johnson to promote STEMREGEN;, a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). (VIDEO)

Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients

AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.

EPIC Insurance Brokers & Consultants Acquires Pharmaceutical Strategies Group

SAN FRANCISCO, Calif., Feb. 4, 2021 (SEND2PRESS NEWSWIRE) -- EPIC Holdings, Inc. (EPIC) announced today that it has agreed to acquire Pharmaceutical Strategies Group (PSG). The move incorporates the expertise and resources of the nation's largest independent pharmacy benefit consulting firm into EPIC's Employee Benefits Consulting practice.

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act...

AUSTIN, Texas, Nov. 17, 2020 (SEND2PRESS NEWSWIRE) -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Avila Herbals Announces Manufacturing and Research and Development Agreements with Phoenix Biotechnology

CHRISTIANSBURG, Va., Oct. 28, 2020 (SEND2PRESS NEWSWIRE) -- Avila Herbals, a company specializing in novel botanical extraction techniques for both dietary supplements and pharmaceuticals, announced today that it has signed an exclusive global manufacturing agreement and a research and development agreement with Phoenix Biotechnology.

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass., Oct. 6, 2020 (SEND2PRESS NEWSWIRE) -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease.

US Pharmaceutical Corporation® Introduces Patented Hylafem® pH Vaginal Suppositories Consisting of Boric Acid in a Probiotic Blend

DECATUR, Ga., Aug. 17, 2020 (SEND2PRESS NEWSWIRE) -- US Pharmaceutical Corporation, the probiotic and nutritional supplement company, launches Hylafem pH vaginal suppositories, a unique, patented, homeopathic suppository product which efficaciously tackles recurring women's vaginal health issues.

FEATURED NEWS

NATIONAL NEWS